- Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis
-
Quiros JR, Ross-Comptis J, III DH, Sarfraz A, Sarfraz Z, Grigoryan Z, Romero KA, Gapizov A, Príncipe-Meneses FS, Somagutta MR, Riva-Moscoso A, Kapasi A
- KMID: 2521222
- Infect Chemother.
- 2021 Sep;53(3):436-448.
- doi: 10.3947/ic.2020.0126
Background: The cause of end-organ damage and acute respiratory distress syndrome (ARDS) in coronavirus disease 2019 (COVID-19) patients is postulated to be connected to the uncontrolled increase of pro-inflammatory cytokines.... -
- CITED
-
- Close
- SHARE
-
- Close
